Harbin Pharmaceutical Group Co.,Ltd.(600664.SH)
Registered Capital:
1242.01(RMB MLN)

Introduction from Google Finance
Harbin Pharmaceutical Group Co., Ltd. is principally engaged in the manufacture and distribution of pharmaceuticals. The Company's major products are antibiotics, Chinese medicines, chemical drugs, over-the-counter (OTC) medicines, healthcare products, biological engineering, animal vaccines and animal remedies, among others, including injections, powder injections, oral liquid, tablets and capsules, among others. The Company also involves in the manufacture of medical equipment and pharmaceutical manufacturing devices, pharmaceutical commerce, manufacture, packaging and printing of pure water, drinks, starch, feedstuff additives, food and cosmetics, as well as the manufacture and distribution of healthcare food and daily used chemical products. The Company distributes its products in domestic and overseas markets.
News      more..
Introduction from Company WebSite

Harbin Pharmaceutical Group Co., Ltd. is a state-owned joint venture after restructuring through capital and stock increases in 2005. It sets up two public companies listed on Shanghai Stock Exchange (i.e., Harbin Pharmaceutical Group Holding Co., Ltd. and Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd.), and 27 wholly-owned, holding and joint-stock companies. The registered capital totals 3.7 billion yuan, the total assets amounts to 14.65 billion yuan, and the ownership interests reach 8.96 billion yuan. Staffed with total 18, 382 employees, the Group has 12 affiliated pharmaceutical companies.
Harbin Pharmaceutical Group Co., Ltd. integrates pharmaceutical manufacturing, trade, and scientific research as a whole, covering the seven industrial fields of antibiotics, chemical pharmaceutical preparations, non-prescription drugs and health-care products, traditional Chinese medicines, bioengineering medicines, animal vaccines and veterinary drugs, and pharmaceutical circulation. Its products are of more than 1,000 varieties, over 20 kinds of dosage formulations, and 7 major series, involving antibiotic bulk drugs and powder for injection, Chinese patent drugs, Chinese medicine powder for injection, and comprehensive preparations. The Group has an annual output capacity of 13,000 tons of antibiotics and intermediates, 3 billion of western medicine powder for injection, 400 million of point injection, 20 billion of tablets, 12.5 billion of capsules, 3 billion of oral liquid, and 45 billion of animal vaccines. The affiliated manufacturers of the Group have all passed GMP certification, the main circulation enterprises, GSP certification, and General Pharmacy Factory, Sanjing Medicine Co., Ltd., and some other subordinated enterprises, the certifications of ISO9001, ISO14001 and OHSAS18001. Harbin Pharmaceutical Group Co., Ltd. has established more than 130 sales offices spreading over 30 major cities in the country and 200 retail chain pharmacies to form the marketing network with wide coverage and strong functions.
Over the years, Harbin Pharmaceutical Group Co., Ltd., under the tenet of “Manufacturing authentic drugs and marking a honest enterprise”, has achieved the rapid-increasing market share, the gradually-expanding business scopes, and the annual capacity to earn foreign currency through export of 100 million US dollars thanks to the introduction of some products to the European, Asian, African, and the North American markets. In line with the corporate philosophy of “Opposing Force, Original Ideas, Virtue Supremacy”, the Group has actively carried out the brand innovation strategy and has won universal praises from all sectors of society. Through the assessment conducted by the domestic authoritative institution of brand value – Beijing Brand Assets Value Assessment Co., Ltd., the Group is rated as one of the Most Valuable Chinese Medicine Brands with the value of 14.525 billion yuan. The Group has four Chinese Well-known Trademarks of “Hayao”, “Sanjing”, “Shiyitang”, and “Gaizhonggai”, ranking first in the whole industry and in the three northeastern provinces.


2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号